According to a recent LinkedIn post from Cagent Vascular Inc, the company’s Serranator device was used in a clinical case involving decreased flow in an arteriovenous (AV) fistula, where imaging revealed focal cephalic arch stenosis. The lesion was treated with a 7.0×40 mm Serranator balloon, followed by an 8.0×60 mm drug-coated balloon, reportedly resulting in no residual stenosis on the final angiographic run.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post highlights the use of serration-based angioplasty as a lesion-preparation tool, particularly in larger vessels relevant to dialysis access. For investors, the case example may suggest growing clinical adoption and utility of Cagent Vascular’s technology in AV fistula maintenance, which could support future revenue growth, strengthen its positioning in the endovascular and dialysis-access segments, and enhance its competitive profile versus conventional angioplasty solutions.